Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes

NCT06706284 · Recruiting

Last updated 2026-05-28

This clinical trial is testing the effects of a GLP-1 receptor agonist on blood sugar control and weight loss in adults with both spinal cord injuries and type 2 diabetes.

Status Recruiting Currently enrolling participants.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Non-randomized, single-blind treatment study

Participants 50 people Planned (estimated).

Who can join Ages 18–70 · all sexes

Timeline Started 2025-04 · est. completion 2029-03

Where 2 sites · United States

What this study is testing ClinicalTrials.gov NCT06706284 ↗

Description as written by the study sponsor.

It is not known whether a new diabetes drug, semaglutide, is an effective treatment for type 2 diabetes for persons with spinal cord injury (SCI), a population at higher risk for this condition. Therefore, this study looks at the effect of semaglutide on glucose levels in the body and other information about type 2 diabetes and obesity.

Treatments tested

Semaglutide Injectable Product also known as Ozempic Drug

A GLP-1 inhibitor used to control T2DM
Placebo also known as Saline solution Other

Saline solution will be administered with the same frequency as semaglutide and participants will be instructed how to use the saline in the same manner as the active drug group.

Main thing measured	Glucose tolerance
Sponsor	Marzieh Salehi
Conditions studied	Spinal Cord Injuries, Type 2 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06706284 ↗